UnitedHealthcare · Voquezna · US health-plan appeal rights

Voquezna denied as duplicate or overlapping therapy by UnitedHealthcare?

Q: How long do I have to appeal a UnitedHealthcare Voquezna denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

If two medications appear duplicative on paper but serve different clinical purposes (e.g., short-acting vs long-acting), the appeal needs to spell out the clinical rationale for both.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-10

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What UnitedHealthcare typically requires

UnitedHealthcare's specific coverage criteria for voquezna are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: OptumRx Voquezna (Vonoprazan) Prior Authorization

The UnitedHealthcare angle on Voquezna

## Why UnitedHealthcare Denies Voquezna as Duplicate Therapy

Voquezna (vonoprazan) is a potassium-competitive acid blocker (PCAB) — a mechanistic class distinct from traditional proton pump inhibitors (PPIs). UnitedHealthcare may issue a duplicate-therapy denial when it identifies that the patient is already filling a PPI or another acid-suppressive agent, and its automated system flags the combination as therapeutic duplication. This denial is often based on pharmacological category, not individualized clinical review.

The core appeal argument is that vonoprazan and PPIs are not true duplicates: they work by different mechanisms, have different pharmacokinetic profiles, and the FDA approved vonoprazan precisely for cases where PPI-based regimens are used — including Helicobacter pylori eradication regimens where vonoprazan replaces a PPI component. Your prescriber is best positioned to articulate why the clinical situation calls for vonoprazan rather than a PPI.

## Your Appeal Rights

Internal appeal (ERISA §503 / ACA): File within the deadline on your denial letter. The appeal should be reviewed by a pharmacist or clinical reviewer, not just automated edits.
External review (ACA §2719): If the internal appeal fails, request binding independent external review within approximately four months of the final internal denial. An IRO with pharmacy expertise is well-suited to evaluate mechanism-of-action distinctions.
Expedited review: Available if the clinical situation is urgent.

## Documentation to Gather

1. Prescriber's rationale letter — a letter explaining why vonoprazan is being prescribed instead of (not in addition to) the prior acid-suppressive therapy, or why the combination is clinically intentional, referencing the FDA-approved prescribing label and applicable guideline organizations (e.g., ACG). 2. Prior therapy outcomes — documentation of the patient's experience with PPI-based treatment: duration of use, response, any inadequate acid control or treatment failure. 3. FDA prescribing label for Voquezna — highlight the approved indications and the distinct mechanism section to rebut the "duplicate" classification. 4. Current diagnosis and clinical status — confirm the diagnosis (e.g., H. pylori infection, erosive esophagitis, NERD) and the indication for which vonoprazan is prescribed. 5. Medication list — a current reconciled medication list showing what is and is not being taken, to clarify whether true concurrent use is occurring.

## Criteria-Mapping Structure

| UHC Denial Basis | Rebuttal Evidence | |---|---| | Duplicate acid suppression on profile | Medication reconciliation; prior agent discontinued or being replaced | | Same therapeutic category as PPI | FDA label — PCAB vs. PPI mechanism distinction | | No clinical differentiation documented | Prescriber letter citing treatment history and clinical rationale |

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other UnitedHealthcare appeals

Other denial reasons for UnitedHealthcare Voquezna

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as experimental or investigational

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-10. Editorial standards: denialhelp.com/authors.